

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

VIVA Foundation for Children with Cancer was set up on 6 February 2006 and registered with the Accounting and Corporate Regulatory Authority (ACRA) as a Company Limited by Guarantee. It was registered under the Charities Act on 25 April 2006. It has also granted an IPC status and a member of Health Endowment Fund since 8 May 2006.

ACRA Registration Number : 200601578E

Charity Registration Number : 01961

IPC Effective Periods : 15 May 2008 – 14 May 2010
15 May 2010 – 14 May 2013

HEF Registration Number : HEF 0105/G

Board of Directors :

<u>Name</u>	<u>Position</u>	<u>Date of Appointment</u>
Foo-Yo Mie Yoen Theresa	Chairman	6 February 2006
Leong Lai Peng	Director/Secretary	6 February 2006
Christina Ong @Christina Fu	Director	6 February 2006
Kwee Liong Keng	Director	6 February 2006
Koh Seow Chuan	Director	20 October 2006
Lee Ming San	Director	20 October 2006
Kuok Oon Kwong	Director	9 November 2007
Mary Ann Wai Sheng Tsao	Director	21 August 2008
Tan Wah Yeow	Director	1 September 2010

Bankers : Citibank Singapore Ltd
Oversea-Chinese Banking Corporation Limited

Auditors : Moore Stephens LLP

MISSION STATEMENT

“Saving lives of children with cancer through excellence in medical care, research, and education.”

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

OBJECTIVES

The goal of Viva Foundation is to improve the survival rate and cure of children with cancer, especially childhood leukemia, in Singapore and around the region. Viva Foundation hopes to achieve this by facilitating a partnership between St Jude Children's Research Hospital ("St Jude") in Memphis, Tennessee, USA, and National University Hospital, Singapore ("NUH") and National University of Singapore ("NUS"). Viva University Children's Cancer, established by VIVA Foundation in NUH, National University Health System (NUHS) aspires to become a world class center for the treatment of pediatric cancers adopting state-of-the-art medical practices in terms of organization, clinical treatment, care and research.

PROGRAMMES / ACTIVITIES

VIVA-University Children's Cancer Centre (VUC³)

The VUC³ is housed in Ward 88, Kent Ridge Wing in the National University Hospital. It is a one-stop centre with state-of-the-art transplant facilities; complete with the inpatient wards and outpatient consultation and day therapy areas so that every child with cancer will receive most of their care in one holistic environment. This facility is the seat of the St. Jude-Viva International Outreach Program to train local and regional doctors and nurses and the Viva Foundation's Centre of Excellence for the treatment of childhood cancer.

VUC³ was officially operational in February 2008. An outline of the annual patient workflow is outlined in the figures below. The number of patients seen in VUC³ is compared to the baseline numbers (2006 and 2007) prior to set up of VUC³. Consistent with NUHS being a tertiary academic medical centre for the region, our patient load includes a large number of foreign patients referred to us for complex therapy and trials.

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

Figure 1. Number of new cases diagnosed in VUC³ at of June 14th 2011.
VUC³ is set up in February 2008. The cases from 2008 onwards are attributed to VUC³.






Figure 2. Number of patients based on nationality: local and foreign



VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010


Figure 3. Number of patient admissions to inpatient and outpatient therapy



VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

Figure 4 Number of Cases – Blood and Marrow Transplantation



ASCR Autologous Stem Cell Rescue

BMT Allogeneic Stem Cell Transplant

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

Clinical Research Programmes

One of Viva's foremost aims is to improve cure rates for childhood cancers through research and enabling novel therapies through the strategic establishment of critical facilities. Through our local expert doctors and researchers, we hope to quickly translate and replicate new discoveries from St. Jude Children's Research Hospital and other top centres into therapies for Asian children. There are currently three areas of focused clinical research:

1. Childhood Leukaemia
2. Cellular-Based Therapy
3. After Completion of Care

Childhood Leukaemia

The Childhood Leukaemia Programme will expand our strengths in treating childhood leukaemias by

1. Setting up a new technology for flow-based MRD which will allow us to accurately predict the risk of relapse in almost every child with leukaemia.
2. Running a state-of-art trial in treating childhood acute myeloid leukaemia by participating in the St Jude AML 2008 study. VUC³ will be the first centre outside USA to accrue patients directly into a St Jude trial.

Cellular-Based Therapy

In Singapore, our small families limit the chances of finding a matched donor for stem cell transplantation; Viva will thus enhance local capability of alternative stem cell transplantation using matched unrelated donors and haploidentical transplantation from parents. Through this program, we hope more children who lack a matched sibling donor can be offered a chance of cure. In 2011, Viva Foundation will fund the St. Jude AML 08 study in VUC³ which incorporates many new exciting therapies like haploidentical natural killer cells to eradicate residual leukemia cells.

The Mrs Lee Kong Chian Chair in Advanced Cellular Therapy and Childhood Leukaemia has been established and structuring of the Chair is currently under review. The Mrs Lee Kong Chian Chair will lead the Paediatric BMT programme in VUC³ and will work closely with adult BMT and haematological malignancies programme in the National University Cancer Institute, Singapore.

After Completion of Therapy (ACT)

With the high cure rates for childhood cancers, surviving after cancer therapy is equally important as the cure. It is critical to discern the long-term side-effects of our therapy and follow survivors of childhood cancer comprehensively to ensure that long-term side-effects are detected early and managed appropriately. This unfortunately is a neglected part of cancer care for children in Singapore. Many children with cancer suffer the effects of chemotherapy and radiotherapy long after their treatment has completed. The Viva Children's Cancer Program aims to develop co-ordinated and systematic After Completion of Therapy Clinics for cancer survivors so the children can realize their full potential. The clinics would provide regular follow up with subspecialty review, administration of vaccinations and investigations to detect any long-term side effects early and to intervene in a timely fashion to optimize the children's health and therefore quality of life.

The After Completion of Therapy Clinic will be sited in the out-patient departments of KKH and NUH. The After Completion of Therapy Programme will have a dedicated doctor and nurse team to systematically co-ordinate the follow up long-term survivors of childhood cancer. There will also be a component sited at the Viva Hub that focuses on the more time intensive process of IQ assessments to help transition survivors back into main stream school and the community.

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

St Jude-Viva International Outreach Programme

This programme aims to develop regional centres of excellence in ASEAN countries. This is achieved by identifying, negotiating and helping to coordinate the setting-up of these centres. This program will provide hands-on and systematic training of foreign doctors and nurses from the region at NUHS for 1-3 years. The trainer program will comprise a core team of up to two doctors and four nurses, each being trained in Singapore and deployed at their respective centres. The centres will establish their own pediatric oncology programs, and support themselves through fundraising by their local charities. The first such program is at the Davao Medical Centre in the Philippines.

Nurses working in the field of childhood cancer are continuously challenged by the diverse age, personal needs and strengths of each family as well as requiring the theoretical knowledge and complex practical skills for the different types of childhood cancer and treatment. We have established a pediatric haematology and oncology programme for registered nurses to give them the specialist skills and expertise required to care for children with cancer. This not only benefits local nurses but students from the region such as Davao, Philippines. Clinical attachments in nursing are also available and this year we have had representatives from the Philippines and India.

St Jude-VIVA Forum in Pediatric Oncology

This annual forum, now in its planning stages for its sixth year, gathers 15 top doctors and scientists from all over the world and provides a platform in Asia for them to exchange information and collaborate in translational clinical research in childhood cancer. Regional leaders from Australia, Hong Kong, Japan, Malaysia, People's Republic of China, Singapore, Taiwan and Thailand will also be presenting. The attendance at the Forum has consistently been around 200 delegates from the region with 237 attending this year, representing 25 countries. Through lectures, Meet the Expert Lunches, practical workshops and publication of the Forum booklet, the aim of Forum is to be conducive to the exchange of ideas and the establishments of collaborations to advance cure rates for children. The website for the Forum is through www.viva.sg/stjude.

Further important ongoing initiatives at the Forum are the Viva-Asia Acute Leukemia and the Viva-Asia BMT (VABMT) Working Groups. Both meetings aim to enhance regional collaboration and provide the opportunity to learn from each other's experience. Leaders from the major Asian cooperative groups will be invited to look at their data and present it in a small group meeting of Asian leaders in this meeting. This will encourage active close collaboration and expand the St Jude-Viva Forum from a passive learning event to an active collaborative Forum. A selection of regional countries will be invited to present their results on the final day of the Forum. The VABMT aims to learn more about each others' centers and has been exploring and implementing opportunities to work together in research and strategic planning in pediatric BMT in the region.

We have also continued with the pre- and post-Forum workshops. This year, the pre-Forum workshop is titled 'Improving Cancer Treatment in Developing Countries' and is dedicated to researchers interested in designing a study protocol for countries with limited resources. This workshop will include study design, components of study such as registration and introduction to statistical analyses. The post-Forum workshop is titled 'Advances in Leukemia Phenotyping and Monitoring by Flow Cytometry'. Its objectives are to learn the principles of using Flow Cytometry in making the diagnosis of childhood leukemias, to develop the skills necessary to apply the principles, to define the minimum panels of antibodies required, to discuss difficult cases encountered in immunophenotyping and to introduce the basic principles of monitoring minimal residual disease.

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

REVIEW OF FINANCIAL YEAR 2010 (1 Jan 2010 – 31 December 2010)

Fundraising Events

<u>Date</u>	<u>Event</u>	<u>Organizers</u>	<u>Venue</u>	<u>Total Amount Raised</u>
5 Nov 2010	Charity Dinner	Viva Foundation	Kuriya Penthouse Restaurant, Orchard Central, Singapore	\$128,000.00

Charitable Events

<u>Date</u>	<u>Event</u>	<u>Sponsor/s</u>	<u>Venue</u>	<u>Activity/ties</u>	<u>Facilitators</u>
3-5 Mar 2010	4 th St Jude-Viva Forum in Pediatric Oncology Theme: Hematological Malignancies and Solid Tumors in Children	Viva	Shangri-La hotel	Gathering top doctors and scientists from all over the world and provide a platform in Asia for them to exchange information and collaborate in translational clinical research in childhood cancer. Total participants: 235	Viva volunteers and NUHS staff.
7 May 2010	Peter and Blue's Forest Adventure	Singapore Dance Theatre	The Singapore Airlines Theatre, Lasalle College of Arts	35 VUC ³ kids and their families were given FOC tickets to watch the performance at 2pm show.	Viva volunteers and CCF social workers.
6 Jun 2010	Queen's Baton Relay XIX Commonwealth Games 2010, Delhi	SAVA Pte Ltd / Singapore National Olympic Council	Swissotel Stamford Hotel, Singapore	One of the longest relays in history, The Queen's Baton Relay came to Singapore. Our children were invited to be one of the Baton bearers.	Viva volunteers and SAVA Pte Ltd

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

REVIEW OF FINANCIAL STATUS AND EXPLANATION OF MAJOR FINANCIAL TRANSACTIONS

The Foundation recorded a surplus of \$676,282 in its financial year for period 1 Jan 2010 to 31 December 2010. We wish to thank our donors, friends, supporters and volunteers who have made significant contributions to the cause of the Foundation.

We have spent \$88,927 for direct expenses on the above-mentioned events and various governance costs of the Foundation.

FUTURE PLANS AND COMMITMENTS

Viva Hub at 8 Sinaran Drive

Far East Organization has generously donated the 3rd floor of Novena Specialist Centre at Sinaran Drive, Novena to Viva Foundation. The Viva Hub is a unique opportunity for Singapore's private, public and philanthropic sectors to work together. The key proposals for the Viva Hub consists of developing a referral diagnostic centre to provide fast, more accurate and cost-effective diagnostics for haematological malignancies; After Completion of Therapy Program for research and rehabilitation of long-term treatment effects; school education programs to seamlessly integrate children with cancer back into the community; and a hub for children's cancer-related charities. Our aim is that the Viva Hub will serve as a platform to enhance academic and community leadership and medical excellence and optimal quality of life for children with cancer.

CentRAL - Referral Diagnostic Centre

A key proposal is the regional referral diagnostic centre – CentRAL (Centre for Translational Research in Acute Leukaemias). Wrong diagnosis and lack of access to good research diagnostic tools is one of the major reasons why children with cancer are not cured in Asean. CentRAL will help bring these new research tests to the children with leukaemia. It will serve to translate all the research done in leukaemia in Singapore, St Jude and the world to patient care in an affordable manner. Singapore Biomedical Research has invested billions of dollars into research. However because leukaemia is not common, there is little interest by pharmaceutical companies to market them.

CentRAL will help address this. Capitalising on Singapore as a transshipment air hub, Viva will be able to provide high quality established research tests to Asian nations within a 6 hour flight from Singapore. We hope to help not just children but adults with leukaemia as well. By working with philanthropic organizations like Lee Foundation, we can make CentRAL into a not-for-profit centre that provides affordable tests to as many children and adults with acute leukaemia from Singapore and Asia.

School for Children with Cancer@ Viva Hub

There is a need for systematic educational program in a safe environment for children during chemotherapy treatment. Children with cancer have weak immune systems due to their cancer and the chemotherapy they received. Because of that they cannot attend normal school and may miss school for up to 1 year. Ideally, they need small class sizes for a low student-to-teacher ratio in a relatively isolated environment to protect the children's health. There is currently no dedicated school that provides for them.

Many patients are completely bored at home and become addicted to non productive computer games. Parents may naturally tend to be overprotective parents given what their child is going

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

through. These children miss their friends and teachers and the majority look forward to returning to school. However, re-entering school is still a big transition for our patients, both in an academic and social capacity. A dedicated environment is the ideal setting to act as a transition program for patients and survivors to rehabilitate their schooling before entering a main stream program if appropriate.

After Completion of Therapy Program – Assessment of Psychological Deficits and Needs of Survivors of Children with Cancer

Seven out of 10 children with cancer diagnosed in Singapore and the developed world are long term survivors. This equates to approximately 77 new long-term survivors each year in Singapore. However due to the exquisite sensitivity of the growing brain and other organs to insult, these long-term survivors may suffer significant disabilities which may turn into severe handicaps if not addressed.

Radiation therapy and chemotherapy to a child's brain may result in significant loss in IQ, memory and ability to process information. In the western world, assessment of these deficits and disability are being studied systematically. In contrast in Asia, including Singapore, Japan and Hong Kong, no such study has been done. There is a dearth of information of the extent of the problem in Singapore and consequently, both Ministry of Education and Ministry of Health do not have specific programs to help long term survivors of children with cancer. This is in contrast with various programs for educationally challenged, autistic children and child development.

Children's Cancer – Related Charities

The Viva Hub will serve as the hub for Institute of Public Character like Viva Foundation and Children's Cancer Foundation for their outreach to long-term survivors and families of children with cancer and harness public support for children with cancer. In addition, the Viva Hub will also serve as the training hub for doctors, nurses and volunteers involved in childhood cancer from Singapore and the region.

Summary

In summary, the Viva Hub provides a unique strategic and synergistic opportunity to:

- Expand Singapore's reputation as an international centre of excellence
- Create the initiatives of the national After Completion of Therapy Clinic
- Clinical translational research on fields not widely addressed in Asia
- New possibilities for national, regional and international collaboration
- Benefits to the childhood cancer community

STATEMENT OF ACCOUNTS

The audited Financial Statements for year ended 31 December 2010 is attached.



Audited FS, FY2010

Company Registration No: 200601578E
Charity Registration No: 001961

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

REPORT OF THE DIRECTORS
AND FINANCIAL STATEMENTS

31 DECEMBER 2010

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

31 DECEMBER 2010

CONTENTS	PAGE
Report of the Directors	1 - 2
Statement by Directors	3
Independent Auditors' Report	4 - 5
Statement of Financial Activities and Income and Expenditure	6
Balance Sheet	7
Statement of Changes in Funds	8
Statement of Cash Flows	9
Notes to the Financial Statements	10 - 22

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

REPORT OF THE DIRECTORS - 31 DECEMBER 2010

The directors are pleased to present their report together with the audited financial statements of Viva Foundation for Children with Cancer (the "Company") for the financial year ended 31 December 2010.

1 Directors

The directors in office at the date of this report are:

Foo-Yo Mie Yoen Theresa
Christina Ong @ Christina Fu
Kwee Liong Keng
Leong Lai Peng
Koh Seow Chuan
Lee Ming San
Kuok Oon Kwong
Mary Ann Wai Sheng Tsao
Tan Wah Yeow (Appointed on 1 September 2010)

2 Directors' Interest in Shares, Debentures, Dividends and Share Options

The Company is limited by guarantee and does not have a share capital. All matters relating to the issue of shares, debentures, dividends and share options are thus not applicable.

3 Directors' Contractual Benefits

Since the end of the previous financial year, no director has received or become entitled to receive a benefit which is required to be disclosed under Section 201(8) of the Singapore Companies Act Cap. 50 by reason of a contract made by the Company or a related corporation with the director or with a firm of which he is a member, or with a company in which he has a substantial financial interest.

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

REPORT OF THE DIRECTORS - 31 DECEMBER 2010


4 Independent Auditors

The independent auditors, Moore Stephens LLP, Public Accountants and Certified Public Accountants, have expressed their willingness to accept re-appointment.

On behalf of the Board of Directors,



Foo-Yo Mie Yoen Theresa



Lee Ming San

Singapore
19 April 2011

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

STATEMENT BY DIRECTORS

31 DECEMBER 2010


In the opinion of the directors:

- (a) the financial statements as set out on pages 6 to 22 are drawn up so as to give a true and fair view of the state of affairs of the Company as at 31 December 2010 and the results, changes in funds and cash flows of the Company for the financial year then ended.
- (b) at the date of this statement, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they fall due.

On behalf of the Board of Directors,



.....
Foo-Yo Mie Yoen Theresa



.....
Lee Ming San

Singapore
19 April 2011

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

We have audited the accompanying financial statements of Viva Foundation For Children With Cancer (the "Company"), as set out on pages 6 to 22, which comprise the balance sheet as at 31 December 2010, and statement of financial activities and income and expenditure, statement of changes in funds and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory notes.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Singapore Companies Act, (Cap. 50) (the "Act") and Singapore Financial Reporting Standards, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and that they are recorded as necessary to permit the preparation of true and fair profit and loss accounts and balance sheets and to maintain accountability of assets.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Singapore Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal controls relevant to the entity's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal controls. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF
VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

(cont'd)


Opinion

In our opinion, the financial statements are properly drawn up in accordance with the provisions of the Act and Singapore Financial Reporting Standards so as to give a true and fair view of the state of affairs of the Company as at 31 December 2010 and the results, changes in funds and cash flows of the Company for the year ended on that date.

Report on Other Legal and Regulatory Requirements

During the course of our audit, nothing came to our attention that caused us to believe that the Company did not comply with the requirements of Regulation 15(1) of the Charities Act, Cap. 37 (Institutions of a Public Character) Regulations 2007 which states that the total fund-raising and sponsorship expenses for the financial period should not exceed 30% of the total gross receipts from fund-raising and sponsorships for the period; and the use of donation money received is not in accordance with the Company's objectives.

In our opinion, the accounting and other records required by the Act to be kept by the Company have been properly kept in accordance with the provisions of the Act.



Moore Stephens LLP
Public Accountants and
Certified Public Accountants

Singapore
19 April 2011

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

STATEMENT OF FINANCIAL ACTIVITIES AND INCOME AND EXPENDITURE
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2010

	<u>Note</u>	<u>2010</u> S\$	<u>2009</u> S\$
<u>Unrestricted General Funds</u>			
Incoming Resources			
Incoming resources from charitable activities	3	93,130	111,014
Incoming resources from generated funds			
- Voluntary income	4	538,758	171,449
- Activities for generating funds	4	128,000	660,250
Other income resources	5	675	5,100
Investment income	6	4,646	5,068
		<u>765,209</u>	<u>952,881</u>
Resources Expended			
Cost of generating funds:			
Charitable activities expenses	7	474	364
Governance costs	8	68,448	122,785
Fund raising expenses	9	20,000	211,940
Other funds expended	10	5	860,000
		<u>88,927</u>	<u>1,195,089</u>
Surplus/(deficit) for the year		676,282	(242,208)
Total Funds Brought Forward		3,069,162	3,311,370
Total Funds Carried Forward		<u>3,745,444</u>	<u>3,069,162</u>

The accompanying notes form an integral part of the financial statements

VIVA Foundation for Children with Cancer

VIVA FOUNDATION FOR CHILDREN WITH CANCER (Incorporated in Singapore)

BALANCE SHEET

AS AT 31 DECEMBER 2010

	<u>Note</u>	<u>2010</u> S\$	<u>2009</u> S\$
<u>Unrestricted General Funds</u>			
ASSETS			
Non-Current Assets			
Equipment	12	<u>1,925</u>	<u>1,112</u>
Current Assets			
Other receivables and prepayments	13	22,055	107,238
Inventories	14	854	854
Cash and bank balances	15	<u>3,731,610</u>	<u>3,181,698</u>
		<u>3,754,519</u>	<u>3,289,790</u>
Total Assets		<u>3,756,444</u>	<u>3,290,902</u>
FUNDS AND LIABILITIES			
FUNDS			
Unrestricted Funds			
General funds		<u>3,745,444</u>	<u>3,069,162</u>
		<u>3,745,444</u>	<u>3,069,162</u>
LIABILITIES			
Current Liability			
Accrued expenses		<u>11,000</u>	<u>221,740</u>
Total Funds and Liabilities		<u>3,756,444</u>	<u>3,290,902</u>

The accompanying notes form an integral part of the financial statements

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

VIVA FOUNDATION FOR CHILDREN WITH CANCER
(Incorporated in Singapore)

REPORT OF THE DIRECTORS - 31 DECEMBER 2010


4 Independent Auditors

The independent auditors, Moore Stephens LLP, Public Accountants and Certified Public Accountants, have expressed their willingness to accept re-appointment.

On behalf of the Board of Directors,



.....
Foo-Yo Mie Yoen Theresa



.....
Lee Ming San

Singapore
19 April 2011

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010

VIVA Foundation for Children with Cancer

Annual Report for Year Ended 31 December 2010
